THE 5-SECOND TRICK FOR HEMGENIX

Number of suitable clients: CDEC reviewed the uncertainty in the amount of patients with reasonably extreme to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some patients that are categorized as having gentle or reasonable sickness might have a critical bleeding phenoty